It's Skin Co Ltd (226320) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of It's Skin Co Ltd stock KRW 8,829, price KRW 10,260, that is 13.9% below the price, quality 69 out of 100. Rating: overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range 8,840 KRW – 27,834 KRW · fair‑value band 7,075 KRW – 11,454 KRW · the 10,260 KRW price screens above the 8,829 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow It's Skin Co in your weekly email
Every Wednesday you see whether It's Skin Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
It'S Hanbul Co., Ltd. develops, manufactures, and sells cosmetics in South Korea and internationally.
Show moreShow less
It offers skin care and makeup products; amino acid toners and ampoules; cleansers, moisturizers, and highlighters; skin hydration solutions; and deodorants under the IT'S SKIN, Flamel MD, Dixionist, Chasin' Rabbits, ICS, ATOPALM, Real Barrier, Derma:B, and ZEROID brands.
The company was formerly known as It'S SKIN Co., Ltd. and changed its name to It'S Hanbul Co., Ltd. in 2017. It'S Hanbul Co., Ltd. was founded in 1989 and is headquartered in Seoul, South Korea.
Stock analysis
It's Skin Co Ltd (226320) currently trades at 10,260 KRW, while our model-based Fair Value estimate is 8,829 KRW, 14% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of 17,936 KRW per share, and 8 of the 24 models we run sit above the 10,260 KRW price.
Bear case: the Dividend Discount group reads lowest at 2,430 KRW, and 16 of the 24 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 7,075 KRW (bear) to 11,454 KRW (bull), the price of 10,260 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 69/100 (solid quality), in the Consumer Defensive sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
It's Skin Co Ltd reported revenue of 153B KRW in FY2025 versus 140B KRW in FY2021, a compound +2.3%/yr. Reported net income was 16.7B KRW in FY2025.
Key figures
Market cap 181B KRW (≈ $134M) Micro · P/E ratio 5.6 · P/S ratio 1.06 · EPS (TTM) 1,829 KRW · Dividend yield 2.7% · Net margin 19.4% · Return on equity 9.8% · Return on assets (EBIT) 2.1% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 54 out of 100 (low confidence).
What moves the price
The share trades about 22% below its 52-week high and 16% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −26% fair-value upside, at −14%, 226320 screens cheaper than that median.
Fair Value models
Bear7,075 KRWFair Value 8,829 KRWBull11,454 KRW
Price 10,260 KRW · Downside -13.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (1,333 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+7.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.9%
Start year 2020 (pandemic). Over 10 years: −6.8% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 3 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
≈ +72.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+70.1%
Dividend (yield on the price)2.7%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.3% → 13%
⚠ Revenue per share shrinking 6.6%/yr over ~6Y (margins intact) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
⚠ Approximate: the rate leans on 2025, which sits 68% above its own trend.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−10.7%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about −12.5% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Household & Personal Products · 230 stocks
Beats the industry median on 11/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score69 · Top 25%
Fair Value upside−17.1% · Below median
Profitability
Return on equity (12 months)9.8% · Above median
Return on assets6.1% · Above median
Net margin (12 months)37.7% · Top 25%
Operating margin (12 months)14.8% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)33.3% · Top 25%
Dividend yield (12 months)2.7% · Above median
Valuation Multiplesvs Household & Personal Products median · lower = cheaper
P/E (12 months)5.6× · Cheapest 25%
P/B0.48× · Cheapest 25%
P/S (12 months)2.13× · Pricier than median
Price / free cash flow (fiscal year)13.9× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "It's Skin Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/226320
Frequently asked questions
Is It's Skin Co Ltd (226320) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 8,829 KRW versus a price of 10,260 KRW, about 14% lower (overvalued).
What is the fair value of 226320?
Our model-based fair value for It's Skin Co Ltd is 8,829 KRW (as of Nov 8, 2026), built from audited fundamentals. The current price: 10,260 KRW.
What is the quality score of 226320?
It's Skin Co Ltd has a Quality Score of 69/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for It's Skin Co Ltd (226320)?
Our model-based price target is the fair value of 8,829 KRW (as of Nov 8, 2026) from 24 valuation models. Cautious scenario 7,075 KRW, optimistic scenario 11,454 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the It's Skin Co Ltd stock forecast for 2026?
Our models put fair value at 8,829 KRW, about 14% lower versus a price of 10,260 KRW (overvalued). Cautious scenario 7,075 KRW, optimistic scenario 11,454 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of It's Skin Co Ltd (226320)?
It's Skin Co Ltd reported trailing-twelve-month revenue of about 172B KRW (latest available figure, as of Nov 8, 2026).
Does It's Skin Co Ltd pay a dividend?
It's Skin Co Ltd currently shows a dividend yield of 2.68% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of It's Skin Co Ltd (226320) and when is the ex-dividend date?
It's Skin Co Ltd pays a dividend of 275.00 KRW per share a year, a dividend yield of 2.7%. The last ex-dividend date was Dec 29, 2025. A dividend has been paid every year since at least 2015. The payout ratio is 15.0% of earnings. Free cash flow covers the dividend 5.43 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into It's Skin Co Ltd (226320)?
For today's price to be fair in a discounted-cash-flow model, It's Skin Co Ltd would have to grow free cash flow by -10.7 % per year for five years (discount rate 11.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +0.9 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of 226320 use?
Our models discount It's Skin Co Ltd at 11.6 %: a base by market capitalisation (micro), damped by beta 0.43, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For It's Skin Co Ltd that is -10.7 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.6 %) and the same formula as our fair value.
How much growth has It's Skin Co Ltd (226320) delivered so far?
Over the past 5 years revenue at It's Skin Co Ltd grew +0.9 % a year. The price currently implies free-cash-flow growth of -10.7 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of It's Skin Co Ltd (226320) growing?
The median revenue growth in the sector is +3.6 % a year. That is the yardstick for the growth priced into It's Skin Co Ltd (-10.7 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of It's Skin Co Ltd (226320)?
The free-cash-flow yield on the price is 14.55 %: that much free cash flow It's Skin Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of It's Skin Co Ltd (226320)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For It's Skin Co Ltd it is 8,829 KRW per share (as of Nov 8, 2026), against a price of 10,260 KRW. It is the blended result of 24 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is It's Skin Co Ltd stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 226320 trades above its calculated fair value: price 10,260 KRW, fair value 8,829 KRW, a gap of about −14% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 226320?
No. The price is what the market pays today (10,260 KRW); the fair value is what the company's own numbers justify (8,829 KRW). For It's Skin Co Ltd the two are 1,431 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is It's Skin Co Ltd worth?
The market values It's Skin Co Ltd at about 181B KRW (market capitalisation, as of Nov 8, 2026). Per share that is 10,260 KRW; our models calculate a fair value of 8,829 KRW per share.
What do the bullish and bearish scenarios say about 226320?
Our models span a range for It's Skin Co Ltd: cautious scenario 7,075 KRW, base 8,829 KRW, optimistic 11,454 KRW per share (as of Nov 8, 2026, price 10,260 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 226320?
It's Skin Co Ltd trades at a price-to-earnings ratio of 5.6 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 8,829 KRW is built from several models across several years. Median P/E at fiscal year-end, 5 fiscal years (2017 to 2025), reported earnings: 29.1. Other multiples: P/B 0.5, P/S 2.1, EV/EBITDA 10.0.
How solid is the balance sheet of It's Skin Co Ltd (226320)?
Balance-sheet figures for It's Skin Co Ltd (as of Nov 8, 2026): return on equity 9.8%. They feed the Quality Score of 69/100, which measures business quality independently of the share price.
How far is 226320 from its 52-week high?
It's Skin Co Ltd trades at 10,260 KRW, about 22% below its 52-week high of 13,160 KRW and 16% above the low of 8,840 KRW (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 8,829 KRW is for.
Which stocks are comparable to It's Skin Co Ltd?
From the same area (Consumer Defensive) we also value Colgate-Palmolive Company, Hindustan Unilever Limited, The Estée Lauder Companies Inc, Henkel AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is It's Skin Co Ltd stock attractive at the current price?
The data as of Nov 8, 2026: price 10,260 KRW, calculated fair value 8,829 KRW (−14%), Quality Score 69/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 226320 calculated?
We run It's Skin Co Ltd through 24 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 8,829 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. It's Skin Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of It's Skin Co Ltd (226320)?
The closing price on Nov 9, 2026 was 10,260 KRW. Our model-based fair value is 8,829 KRW, about 14% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with It's Skin Co Ltd right now?
Solid but not exceptional quality (69/100) and above fair value, neither a clear bargain nor a standout compounder. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of It's Skin Co Ltd
How large is the market capitalisation of It's Skin Co Ltd (226320)?
The market capitalisation of It's Skin Co Ltd is 181B KRW (≈ $134M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of It's Skin Co Ltd (226320)?
The price-to-sales ratio of It's Skin Co Ltd is 1.06 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of It's Skin Co Ltd (226320)?
Earnings per share at It's Skin Co Ltd are 1,829 KRW (price ÷ EPS = P/E 5.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of It's Skin Co Ltd (226320)?
The dividend yield of It's Skin Co Ltd is 2.7% (payout 15.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of It's Skin Co Ltd (226320)?
The net margin of It's Skin Co Ltd is 19.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of It's Skin Co Ltd (226320)?
The return on equity (ROE) of It's Skin Co Ltd is 9.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of It's Skin Co Ltd (226320)?
On an EBIT basis the return on assets of It's Skin Co Ltd is 2.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of It's Skin Co Ltd (226320)?
The operating margin of It's Skin Co Ltd is 14.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at It's Skin Co Ltd (226320)?
Revenue at It's Skin Co Ltd is growing +33.3% versus a year earlier (3y avg +5.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at It's Skin Co Ltd (226320)?
Earnings per share at It's Skin Co Ltd are growing +44.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does It's Skin Co Ltd (226320) carry?
The net debt of It's Skin Co Ltd is 14.9B KRW (fiscal year 2019, ≈ 0.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch It's Skin Co Ltd in the live analysis
One click puts It's Skin Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 8, 2026